1343987-72-3

Upstream product

• 1343987-71-2 2-pivaloyl-3,4,6-tri-O-benzyl-β-D-glucopyranose 
• 1343987-70-1 allyl 2-pivaloyl-3,4,6-tri-O-benzyl-β-D-glucopyranoside 
• 321896-09-7 allyl 4,6-O-benzylidene-2-O-pivaloyl-α-D-glucopyranoside 
• 93382-48-0 allyl 4,6-O-benzylidene-α-D-glucopyranoside 
• 7464-56-4 1-O-allyl-α-D-glucopyranoside 
• 83921-79-3 allyl 2-O-acetyl-3,4,6-tri-O-benzyl-β-D-glucopyranoside 
• 2873-29-2 D-glucal triacetate 
• 55628-54-1 3,4,6-tri-O-benzyl-D-glucal 
• 2280-44-6 D-Glucose 
• 100-39-0 benzyl bromide 

Downstream Products

• 1343988-82-8 allyl 3-O(2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl)-2-O-6-O-(4-methoxyphenol)-α-D-glycopyranoside 

Relevant academic research and scientific papers

SYNTHETIC OLIGOSACCHARIDES FOR MORAXELLA VACCINE

The present invention provides synthetic Moraxella catarrhalis lipooligosaccharide (LOS)-based oligosaccharides and conjugates containing various M. catarrhalis serotype-specific oligosaccharide antigens or various core M. catarrhalis oligosaccharide structures or motifs corresponding to one or more of the three major serotypes and/or members within a given serotype. The oligosaccharides may be synthesized by a chemical assembly methodology relying on a limited number of monosaccharide and disaccharide building blocks. The invention further provides M. catarrhalis LOS-based immunogenic and immunoprotective compositions and antibodies derived therefrom for diagnosing, treating, and preventing infections caused by M. catarrhalis.